Institut National De La Sante Et De La Recherche Medicale

Université Paris Est Creteil Val De Marne

Assistance Publique-hopitaux De Paris

Assistance Publique - Hopitaux De Paris (aphp)

Inserm

Sophie Hue

Yves Levy

Jean-Daniel Lelievre

The invention provides diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on the expression level of a combination of such markers in a biological sample obtained from said individual. Such combination of markers is useful for determining the susceptibility to nosocomial infections of an individual. Such combination of markers is also useful for predicting whether an individual will respond to active vaccination and become protected against recurring diseases.

Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections

The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

Soluble ST2 as a marker for risk of mortality in HIV-infected subjects

Growing community of inventors

Créteil, France

Sophie Hue